MYD88 and diffuse large B-cell lymphoma: Notably, among the six SPIBhigh/BATFlow-ABC-DLBCL patients with MYD88 mutations all but one survived for 5 years or more, the patient who died during follow-up was an 85-year-old who survived for 2.5 years but had not received treatment with curative intent.